L-Dopa Pharmacokinetic Profile with Effervescent Melevodopa/Carbidopa versus Standard-Release Levodopa/Carbidopa Tablets in Parkinson’s Disease: A Randomised Study

Figure 3

L-dopa plasma concentrations for patients in Cohort 3 (dose administration every 3 hours) receiving V1512 solution plus entacapone 200 mg (a) or L-dopa/carbidopa 100/25 mg standard-release tablets plus entacapone 200 mg (b). All patients with data available for the pharmacokinetic analyses were included; patients with significant violations that may have invalidated or biased the results of the pharmacokinetic evaluations were excluded. –·–·–· = lower limit of quantification (10 ng/mL).

(a)

(b)